Eliminating oncogenic RAS: back to the future at the drawing board
Sign Up to like & getrecommendations! Published in 2023 at "Biochemical Society Transactions"
DOI: 10.1042/bst20221343
Abstract: RAS drug development has made enormous strides in the past ten years, with the first direct KRAS inhibitor being approved in 2021. However, despite the clinical success of covalent KRAS-G12C inhibitors, we are immediately confronted… read more here.
Keywords: small molecule; back future; oncogenic ras; eliminating oncogenic ... See more keywords